Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
680 participants in 3 patient groups
Loading...
Central trial contact
Immunocore Medical Information EU; Immunocore Medical Information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal